Vor Biopharma Inc. announced additional clinical data from its Phase 1/2a study of trem-cel in patients with acute myeloid leukemia, including patient outcomes and safety information.
AI Assistant
VOR BIOPHARMA INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.